MGI Tech Co., Ltd. (referred to as MGI) is committed to building core tools and technology to lead life science through intelligent innovation. With a focus on R&D, production and sales of DNA sequencing instruments, reagents, and related products, MGI provides real-time, panoramic, and life course equipment and systems for precision medicine, precision agriculture, precision healthcare and other relevant industries. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation.
As of September 30, 2023, MGI has more than 2,900 employees, and 36% of whom are R&D personnel. Founded in 2016, MGI operates in more than 100 countries and regions, serving more than 2,600 customers. It has established scientific research and production bases, global training and service network in many countries and regions around the world. MGI is one of the few companies in the world that can independently develop and mass-produce low-, medium- and high-throughput clinical gene sequencers from GB to TB. Providing real-time, comprehensive, life course solutions, its vision is to lead life science innovation.